EQ News and Press, Equillium Inc.

2024-06-12 08:22:15 ET More on Equillium Equillium posts early mid-stage data for hair loss therapy Seeking Alpha’s Quant Rating on Equillium Read the full article on Seeking Alpha For further details see: Equillium to join Russell Microcap Index

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...

A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 74.6% to $0.46 on volume of 265,324,361 shares MicroAlgo Inc. (MLGO) rose 669.9% to $12.01 on volume of 183,977,846 shares PROSHARES TRUST (SQQQ) fell 0.7% to $9.86 on volume of 124,114,596 shares Faraday ...

A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 115.1% to $0.5667 on volume of 77,631,052 shares MicroAlgo Inc. (MLGO) rose 284.0% to $5.99 on volume of 40,752,997 shares Crown Electrokinetics Corp. (CRKN) fell 13.8% to $0.1016 on volume of 28,247,104 sha...

2024-06-04 08:52:26 ET More on Equillium Top 10 best performing biotech stocks of 2024 so far Seeking Alpha’s Quant Rating on Equillium Historical earnings data for Equillium Financial information for Equillium Read the full article on Seekin...

20% of all subjects that completed the 24-week treatment period achieved SALT ≤ 20 29% of completed subjects with moderate to severe disease (baseline SALT 35 to <95) achieved SALT ≤ 20 EQ101 was well tolerated in subjects with alopecia areata with no serious adve...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Jefferies Global Healthcare Conference taking place at the Marriott Marquis in New Yor...

More than 100 patients enrolled from over 100 clinical trial sites active in 12 countries Delivery of the interim data review to Ono Pharmaceutical Co. Ltd. (Ono) expected during Q3 will trigger Ono’s option exercise period Equillium, Inc. (Nasdaq: EQ), a clinical-sta...

2024-05-09 18:02:29 ET More on Equillium Top 10 best performing biotech stocks of 2024 so far Seeking Alpha’s Quant Rating on Equillium Read the full article on Seeking Alpha For further details see: Equillium GAAP EPS of -$0.08, revenue of $10.7M

$32.3 million cash balance at the end of Q1 2024 expected to provide cash runway into 2H 2025 Announced positive topline data from Phase 1b EQUALISE study of itolizumab in lupus nephritis patients, representing the first of two data sets that will trigger Ono Pharmaceutical’s optio...